SEP 17, 2015 02:44 PM PDT

Less Innovation in Non-Hodgkin Lymphoma Treatment Pipeline

The product pipeline for Non-Hodgkin Lymphoma (NHL) exhibits a lower degree of innovation than both the industry and oncology average, with just 28 percent of all pipeline products, or 33 percent of the pipeline for which there is a disclosed molecular target, categorized as first-in-class, according to business intelligence provider GBI Research. The report said that this is in comparison to industry, breast cancer and lung cancer innovation rates of 43 percent, 57 percent and 59 percent, respectively.
There is less scope for targeted therapy for NHL. 
GBI’s latest report claims that while NHL, collectively, is the sixth to tenth most common cancer dependent on territory, each individual subtype is classified as an orphan disease. With significant differences in each subtype’s genetic profile and current treatment, there is reduced scope for the development of a targeted therapy with cross-subtype activity, explains Katie Noon, senior analyst, GBI Research, in an article in Drug Discovery & Development
 
This factor makes NHL drug development a less attractive investment than other indications in oncology, especially as survival durations across many NHL subtypes are relatively strong, and likely the reason for low first-in-class innovation levels. There is innovation in varying degrees across the majority of molecular target families and development stages for NHL therapeutics, rather than limited to a particular subset of therapies.
 
Additionally, according to the report, there is a considerable range of clinical potential across treatments with first-in-class status, especially those restricted to the early-stage NHL pipeline. Some targets, including spleen tyrosine kinase, have a great deal of supporting scientific and clinical evidence, while others have offered mixed results in preclinical studies and lack clarity on their role in disease pathophysiology.
 
GBI report also adds that despite the difficulty of several targeted NHL therapies in achieving improved efficacy rates, the development of such treatments remains of key interest across NHL. Noon says that it is hoped that one of these many targeted therapy pipeline products will repeat the success seen with rituximab, which greatly changed the NHL treatment landscape after its approval. Gaps in the treatment algorithm include “maintenance therapies to prolong initial or subsequent durations of remission, and improved therapies for relapsed patients, particularly those with a second or subsequent relapse,” the report says.
 
According to the American Cancer Society, non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts the lymphocytes, part of the body’s immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues, including the spleen and bone marrow.
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 06, 2018
Cell & Molecular Biology
JUN 06, 2018
New Role for Protein Complex Provides Insight Into Cancer Development
Researchers found that RSC plays an important role in chromosome distribution....
JUN 21, 2018
Immunology
JUN 21, 2018
The Silver Tsunami: An Aging Immune System and Cancer
Why do cases of cancer become more common as we get older? Scientists interested in explaining the so-called “Silver Tsunami” phenomenon look t...
JUL 26, 2018
Genetics & Genomics
JUL 26, 2018
When a Cancer Gene Switches Sides
All cells carry a gene named p53, which has a vital role in shielding the body from cancer. But it can betray cells too....
JUL 30, 2018
Cancer
JUL 30, 2018
Challenges Coming to a Cancer Diagnosis in the UK
England's NHS Cancer Patient Experience Survey shows some cancers take longer for GPs to recognize....
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
Loading Comments...